Literature DB >> 15854533

[Therapeutic effects of RNA interference targeting HIF-1 alpha gene on human osteosarcoma].

Qiang Wu1, Shu-Hua Yang, Shu-Nan Ye, Rui-Ying Wang.   

Abstract

OBJECTIVE: To investigate the inhibition effect of the small hairpin RNA (shRNA) targeting HIF-1alpha gene on the growth of osteosarcoma in vitro and in vivo.
METHODS: The small hairpin RNA (shRNA) eukaryotic expression vector targeting HIF-1alpha gene, named pSilencer-HIF, was constructed and transfected into cultured human osteosarcoma cell of line SaOS-2 via liposome reagent. Then the osteosarcoma cells were cultured under chemical hypoxia conditions. The inhibition effects on HIF-1alpha gene were determined by semi-quantitative reverse transcription PCR and Western blot analysis. The in vitro cellular growth activities were assayed by MTT colorimetry. The cell apoptosis was studied by electron microscopy, TUNEL assay, and annexin V/PI double staining. Eighteen Balb/C mice were randomly divided into 3 equal groups to be inoculated with SaOS-2/shRNA, SaOS-2/neo (blank vector), or SaOS-2 subcutaneously respectively and then the appearance and size of tumors were observed. Four weeks later the mice were killed and the volumes of tumor were calculated so as to evaluate the therapeutic effects of shRNA.
RESULTS: The successful construction of pSilencer-HIF plasmid was identified with sequencing. After the shRNA expression vector was transfected into the SaOS-2 cells, the expression of HIF-1alpha gene was inhibited significantly (by 90%). The cellular growth activities in the SaOS-2 cells transfected with pSilencer-HIF plasmid decreased obviously in hypoxia culture. After 72 hours of exposure to hypoxia, electron microscopy and TUNEL assay showed classic apoptosis characters in the SaOS-2 cells transfected with pSilencer-HIF plasmid with an apoptosis rate of 18.71% +/- 0.98%, significantly higher than those in the negative control group transfected with pSilencer-neo and in the nontransfected group (both P < 0.01). The growth speed and formation rate of xenograft tumor in pSilencer-HIF transfected mice slowed down significantly. A lot of necrotic tissues could be observed in the pSilencer-HIF transfected group by HE staining, however, there was no similar inhibitive effect in the control groups.
CONCLUSION: shRNA targeting HIF-1alpha gene blocks the hypoxia transduction pathway efficiently and inhibits the growth of osteosarcoma cells.

Entities:  

Mesh:

Year:  2005        PMID: 15854533

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  6 in total

1.  Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.

Authors:  Yong Chen; Yun Yang; Zhanna Yuan; Chunmeng Wang; Yingqiang Shi
Journal:  Oncol Lett       Date:  2012-02-10       Impact factor: 2.967

2.  Hypoxia markers in human osteosarcoma: an exploratory study.

Authors:  Hiroo Mizobuchi; José Manuel García-Castellano; Shaji Philip; John H Healey; Richard Gorlick
Journal:  Clin Orthop Relat Res       Date:  2008-06-05       Impact factor: 4.176

3.  DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas.

Authors:  Tu Hu; Nengbin He; Yunsong Yang; Chengqian Yin; Nianli Sang; Qingcheng Yang
Journal:  J Exp Clin Cancer Res       Date:  2015-02-28

Review 4.  The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration.

Authors:  Lihong Fan; Jia Li; Zefeng Yu; Xiaoqian Dang; Kunzheng Wang
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

5.  Curcumin may serve an anticancer role in human osteosarcoma cell line U-2 OS by targeting ITPR1.

Authors:  Zhanpeng Luo; Dawei Li; Xiaobo Luo; Litao Li; Suxi Gu; Long Yu; Yuanzheng Ma
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

6.  MicroRNA-20b Downregulates HIF-1α and Inhibits the Proliferation and Invasion of Osteosarcoma Cells.

Authors:  Ming Liu; Dan Wang; Ning Li
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.